Amanda is a senior reporter with more than 20 years' experience as a writer and editor. She has previously been a staff writer for The West Australian and a journalist for The Sunday Times, the Kalgoorlie Miner, Australia’s Mining Monthly and ResourceStocks. While living in the UK, Amanda wrote for the Newsquest group. She has also written for a broad variety of Australian online news outlets and was a publications manager for the Western Australian government. Amanda has a master’s degree in international journalism from the University of Western Australia, an undergraduate degree in commerce, and a diploma in journalism from the British National Council for the Training of Journalists. She has strong interests in history and book publishing.
The company’s chief executive Nicholas Simms will speak at the first ASX Small and Mid-Cap Conference in Sydney on Thursday.
Cynata can produce enough stem cells that a mesenchymal stem cell product could be produced with just one donor.
The company is enjoying revenue growth after updating its influenza-and-pathogens test and signing a major contract.
The company will use the capital raised as fuel for distributing its products in Australian and international markets.
The company has started manufacturing the product and plans to launch it later this year.
The deal is part of a concerted effort by the company to “unlock shareholder value” with strategic deals that open up new markets.
The investor event starts at 3pm on the main drag of the trendy Perth suburb of Mt Lawley.
The biotechnology company is focused on its R&D program and is funded with a $1.9 million R&D loan from Paddington Street Finance Pty Ltd.